第一医药(600833) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 462,073,365.11, representing a year-on-year increase of 0.65%[5]. - The net profit attributable to shareholders for the same period was CNY 36,053,836.02, reflecting a significant increase of 21.75% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 43.55%, amounting to CNY 4,445,109.23, primarily due to reduced sales of related materials[5][8]. - The basic earnings per share for Q1 2024 were CNY 0.1616, up by 21.79% year-on-year[5]. - The weighted average return on net assets was 3.51%, an increase of 0.47 percentage points compared to the previous year[5]. - Total profit for Q1 2024 was CNY 47,904,890.21, an increase of 23.3% compared to CNY 38,846,843.85 in Q1 2023[18]. - The net profit for Q1 2024 was CNY 36,053,836.02, an increase of 21.8% compared to CNY 29,612,934.80 in Q1 2023[19]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.1616, up from CNY 0.1327 in Q1 2023, reflecting a growth of 21.5%[19]. Cash Flow and Liquidity - The net cash flow from operating activities saw a drastic decline of 90.65%, totaling CNY 10,368,722.94, mainly due to the timing of sales refunds[5][8]. - Cash flow from operating activities generated a net amount of CNY 10,368,722.94, a significant decrease of 90.7% from CNY 110,910,482.82 in the same period last year[23]. - The company’s operating cash inflow decreased by 13.4% from CNY 605,721,343.28 in Q1 2023 to CNY 524,458,564.26 in Q1 2024[23]. - Total cash inflow from investment activities was CNY 90,261,106.91, while cash outflow was CNY 113,582,191.78, resulting in a net cash outflow of CNY 23,321,084.87[24]. - Cash flow from financing activities yielded a net inflow of CNY 4,362,688.95, compared to a net outflow of CNY 15,052,939.22 in Q1 2023[24]. - The company reported cash and cash equivalents at the end of Q1 2024 amounting to CNY 390,586,970.52, slightly up from CNY 387,989,848.26 at the end of Q1 2023[24]. - Cash and cash equivalents as of March 31, 2024, were CNY 392,085,876.61, a decrease from CNY 400,027,992.47 as of December 31, 2023[12]. Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 1,855,149,694.08, a decrease of 0.43% from the end of the previous year[6]. - Total assets as of March 31, 2024, were CNY 1,855,149,694.08, slightly down from CNY 1,863,168,849.07 at the end of 2023[14]. - Total liabilities decreased to CNY 809,680,853.37 from CNY 854,715,417.70 at the end of 2023[14]. - Inventory as of March 31, 2024, was CNY 325,347,663.33, down from CNY 332,232,706.24 at the end of 2023[12]. - Short-term borrowings increased to CNY 115,050,458.33 from CNY 95,489,165.29 at the end of 2023[13]. - Non-current assets totaled CNY 782,072,156.02 as of March 31, 2024, up from CNY 745,935,970.69 at the end of 2023[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,724, with the largest shareholder holding 44.95% of the shares[9]. - The company received government subsidies amounting to CNY 40,381,548.64, which are closely related to its normal business operations[7]. Comprehensive Income - The total comprehensive income for Q1 2024 was CNY 37,015,409.34, down from CNY 43,844,285.02 in Q1 2023[19]. - Other comprehensive income after tax for Q1 2024 was CNY 961,573.32, a decrease of 93.3% compared to CNY 14,231,350.22 in Q1 2023[19]. - The company received CNY 90,000,000.00 from the recovery of investments during Q1 2024[24].